Details of the Drug Formulations

General Information of Drug (ID: DMV7YFT)

• Drug Name: Darolutamide Drug Info
• Synonyms: 1297538-32-9; BAY-1841788; N-((S)-1-(3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide; Darolutamide [USAN]; Darolutamide (JAN/USAN/INN); SCHEMBL1814935; SCHEMBL13733117; KS-00000TSX; EX-A759; BLIJXOOIHRSQRB-PXYINDEMSA-N; MolPort-046-033-692; MolPort-044-560-277; AKOS030526387; CS-5174; BAY1841788; DB12941; BAY 1841788; HY-16985; S7559; FT-0700158; J3.501.129C; D11045; J-690121; 1H-Pyrazole-3-carboxamide, N-((1S)-2-(3-(3-chloro-4-cyanophen

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[1]

• Cross-matching ID:
  PubChem CID: 67171867
  CAS Number: 1297538-32-9
  TTD ID: D0DV6D
  INTEDE ID: DR0419
  ACDINA ID: D00989

Full List of Drug Formulations Containing This Drug

Darolutamide 300 mg tablet

Company	Formulation ID	FDA Description
Bayer Healthcare Pharmaceuticals	F23128	Calcium Hydrogen Phosphate; Croscarmellose Sodium; Lactose Monohydrate; Magnesium Stearate; Povidone K 30; Hypromellose 15 Cp; Macrogol 3350; Titanium Dioxide

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019